Literature DB >> 17207716

Coronary collateral function long after drug-eluting stent implantation.

Pascal Meier1, Rainer Zbinden, Mario Togni, Peter Wenaweser, Stephan Windecker, Bernhard Meier, Christian Seiler.   

Abstract

OBJECTIVES: This study was designed to compare coronary collateral function in patients after bare-metal stent (BMS) or drug-eluting stent (DES) implantation.
BACKGROUND: Drug-eluting stents have an inhibitory effect on the production of cytokines, chemotactic proteins, and growth factors, and may therefore negatively affect coronary collateral growth.
METHODS: A total of 120 patients with long-term stable coronary artery disease (CAD) after stent implantation were included. Both the BMS group and the DES group comprised 60 patients matched for in-stent stenosis severity of the vessel undergoing collateral flow index (CFI) measurement at follow-up and for the duration of follow-up. The primary end point of the investigation was invasively determined coronary collateral function 6 months after stent implantation. Collateral function was assessed by simultaneous aortic, coronary wedge, and central venous pressure measurements (yielding CFI) and by intracoronary electrocardiogram during balloon occlusion.
RESULTS: There were no differences between the groups regarding age, gender, body mass index, frequency of cardiovascular risk factors, use of cardiovascular drugs, severity of CAD, or site of coronary artery stenoses. Despite equal in-stent stenosis severity (46 +/- 34% and 45 +/- 36%) and equal follow-up duration (6.2 +/- 10 months and 6.5 +/- 5.4 months), CFI was diminished in the DES versus BMS group (0.154 +/- 0.097 vs. 0.224 +/- 0.142; p = 0.0049), and the rate of collaterals insufficient to prevent ischemia during occlusion (intracoronary electrocardiographic ST-segment elevation > or =0.1 mV) was higher with 50 of 60 patients in the DES group and 33 of 60 patients in the BMS group (p = 0.001).
CONCLUSIONS: Collateral function long after coronary stenting is impaired with DES (sirolimus and paclitaxel) when compared with BMS. Considering the protective nature of collateral vessels, this could lead to more serious cardiac events in the presence of an abrupt coronary occlusion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17207716     DOI: 10.1016/j.jacc.2006.08.043

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  14 in total

1.  Advantages and disadvantages of biodegradable platforms in drug eluting stents.

Authors:  Agustina Rodriguez-Granillo; Bibiana Rubilar; Gaston Rodriguez-Granillo; Alfredo E Rodriguez
Journal:  World J Cardiol       Date:  2011-03-26

Review 2.  Redox-dependent mechanisms in coronary collateral growth: the "redox window" hypothesis.

Authors:  June Yun; Petra Rocic; Yuh Fen Pung; Souad Belmadani; Ana Catarina Ribeiro Carrao; Vahagn Ohanyan; William M Chilian
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

3.  The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy.

Authors:  Shin-ichiro Hayashi; Akitsugu Yamamoto; Fukka You; Kentaro Yamashita; Yuka Ikegame; Masahiro Tawada; Tamotsu Yoshimori; Shigeomi Shimizu; Shigeru Nakashima
Journal:  Am J Pathol       Date:  2009-10-08       Impact factor: 4.307

4.  Short-term exercise training prevents micro- and macrovascular disease following coronary stenting.

Authors:  Xin Long; Ian N Bratz; Mouhamad Alloosh; Jason M Edwards; Michael Sturek
Journal:  J Appl Physiol (1985)       Date:  2010-03-18

5.  Increase in coronary microvascular resistances after recanalisation with drug-eluting stent.

Authors:  A Anselmi; M Harmouche; J Ph Verhoye; H Corbineau; C Mariano; M Maasrani; A Drochon
Journal:  Comput Methods Biomech Biomed Engin       Date:  2014       Impact factor: 1.763

Review 6.  Intravascular optical imaging technology for investigating the coronary artery.

Authors:  Melissa J Suter; Seemantini K Nadkarni; Giora Weisz; Atsushi Tanaka; Farouc A Jaffer; Brett E Bouma; Guillermo J Tearney
Journal:  JACC Cardiovasc Imaging       Date:  2011-09

7.  Restenosis after stenting in symptomatic vertebral arterial orifice disease and considerations for better outcome.

Authors:  Jun Young Chang; Hyun Park; Oki Kwon; Moon-Ku Han
Journal:  Interv Neuroradiol       Date:  2017-01-06       Impact factor: 1.610

8.  Drug-eluting versus bare-metal stent for treatment of saphenous vein grafts: a meta-analysis.

Authors:  Pascal Meier; Emmanouil S Brilakis; Roberto Corti; Guido Knapp; Mehdi H Shishehbor; Hitinder S Gurm
Journal:  PLoS One       Date:  2010-06-10       Impact factor: 3.240

9.  Acute phase proteins activation in subjects with coronary atherosclerosis and micro-vessel coronary circulation impairment.

Authors:  Natale Daniele Brunetti; Roberto Padalino; Luisa De Gennaro; Andrea Cuculo; Luigi Ziccardi; Pier Luigi Pellegrino; Matteo Di Biase
Journal:  J Thromb Thrombolysis       Date:  2008-08-09       Impact factor: 2.300

10.  Perioperative handling of patients on antiplatelet therapy with need for surgery.

Authors:  Matteo Nicola Dario Di Minno; Domenico Prisco; Anna Lilia Ruocco; Pasquale Mastronardi; Salvatore Massa; Giovanni Di Minno
Journal:  Intern Emerg Med       Date:  2009-06-16       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.